Total Funding
52
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
40088
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.
Acquired by 
Concentra Biosciences
- Shawn Leland: Founder and AdvisorPast Role: Elevation Oncology, Founder and Chief Executive Officer
- Joseph Ferra: Chief Executive Officer
About the Company
Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of
any origin that have an NRG1 fusion.
